Project Names: A Historical View of Pharmaceutical Innovation and Incentives for Valued Innovation in the Pharmaceutical Sector both listed on the Policy Work on Affordability & Adoption page.
Dr. Morgan is an expert in the analysis of causes and consequences of prescription drug utilization and spending, as well as the political and economic factors that influence the availability and accessibility of medical technologies. He has published over 100 reports, articles, and book chapters on pharmaceutical policy and has consulted for governments across Canada and abroad. His work seeks to identify policies that achieve balance between three sometimes-competing goals: providing equitable access to necessary care, managing health expenditures, and promoting valued innovation.
Relevant NGDI Articles
Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. Morgan SG, Thomson PA, Daw JR, Friesen MK. Health Policy. 2013 Oct;112(3):248-54.
Growth in private payments for health care by Canadian households. Law MR, Daw JR, Cheng L, Morgan SG. Health Policy. 2013 May;110(2-3):141-6.
Here today, gone tomorrow: the issue attention cycle and national print media coverage of prescription drug financing in Canada. Daw JR, Morgan SG, Thomson PA, Law MR. Health Policy. 2013 Apr;110(1):67-75.
Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces. Morgan SG, Thomson PA, Daw JR, Friesen MK. BMC Health Serv Res. 2013 Jan 31;13:34.
Canadian pharmacare: Looking back, looking forward. Morgan SG and Daw JR. Healthc Policy 2012 8(1):14-23.
Changing scientific and policy paradigms in the pharmaceutical sector: Reflections from a program of research conducted in partnership with decision makers. Morgan S, Cunningham C and Law M.J Popul Ther Clin Pharmacol 2012 19(2):e129.
Drug development: Innovation or imitation deficit? Morgan SG, Cunningham CM and Law MR. BMJ 2012 345:e5880.
Information behaviour of Canadian pharmaceutical policy makers. Greyson DL, Cunningham C and Morgan S. Health Info Libr J 2012 29(1):16-27.
Prescription Drug Use in Pregnancy: A Retrospective, Population-Based Study in British Columbia, Canada (2001-2006). Daw JR, Mintzes B, Law MR, Hanley GE and Morgan SG. Clin Ther 2012 34(1):239-249.e2.
Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Daw JR and Morgan SG. Health Policy 2012 104(1):19-26
The effect of cost on adherence to prescription medications in Canada. Law MR, Cheng L, Dhalla IA, Heard D and Morgan SG. CMAJ 2012 184(3):297-302.
The cost of drug development: A systematic review. Morgan S, Grootendorst P, Lexchin J, Cunningham C, and Greyson D. Health Policy 2011, Vol100:1:4-17.
The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada. Hanley GE, Morgan S, Barer M, and Reid RJ. Health Policy 2011, Vol101:2:185-194.